Table 3.
Association between miR-34a expression levels and overall survivals
| No.of studies | No.of patients | Pooled HR (95%CI) | Meta regression p-value | Heterogeneity | |||
|---|---|---|---|---|---|---|---|
| Fixed | Random | I2 | p-value | ||||
| Overall | 18 | 1691 | 1.600 (1.44–1.77) | 1.86 (1.52–2.28) | 58.7% | 0.001 | |
| Ethnicity | 0.806 | ||||||
| Asian | 15 | 1456 | 1.58 (1.42–1.76) | 1.82 (1.48–2.24) | 55.2% | 0.005 | |
| Caucasian | 3 | 235 | 1.86 (1.25–2.76) | 2.20 (0.90–5.37) | 78.6% | 0.009 | |
| Sample Size | 0.979 | ||||||
| ≥ 100 | 7 | 937 | 1.51 (1.34–1.69) | 1.61 (1.35–1.92) | 36.1% | 0.153 | |
| <100 | 11 | 754 | 1.98 (1.59–2.48) | 2.00 (1.37–2.93) | 63.2% | 0.002 | |
| NOS Scores | 0.978 | ||||||
| ≥ 8 | 11 | 1100 | 1.53 (1.36–1.71) | 1.75 (1.42–2.16) | 49.5% | 0.031 | |
| < 8 | 7 | 591 | 2.00 (1.56–2.55) | 1.87 (1.20–2.93) | 65.8% | 0.008 | |
| Specimen | 0.933 | ||||||
| tissue | 17 | 1532 | 1.57 (1.41–1.75) | 1.87 (1.50–2.33) | 60.2% | 0.001 | |
| plasma | 1 | 159 | 1.88 (1.34–2.63) | 1.88 (1.34–2.63) | – | – | |
| Cancer Types | 0.494 | ||||||
| EC | 2 | 210 | 1.69 (1.04–2.74) | 1.87 (0.88–4.00) | 45.6% | 0.175 | |
| GC | 5 | 457 | 1.33 (1.13–1.57) | 1.25 (0.59–2.65) | 68.3% | 0.013 | |
| HCC | 4 | 339 | 1.60 (1.33–1.92) | 1.84 (1.30–2.59) | 48.7% | 0.119 | |
| PC | 4 | 460 | 2.27 (1.77–2.89) | 2.59 (1.69–3.97) | 57.1% | 0.072 | |
| CRC | 2 | 148 | 1.59 (1.03–2.47) | 1.59 (1.03–2.47) | 0.0% | 0.556 | |
| GBC | 1 | 77 | 2.37 (1.11–5.06) | 2.37 (1.11–5.06) | – | – | |
Abbreviations: 95%CI 95% confidence interval, CRC colorectal cancer, EC esophageal cancer, GBC gallbladder cancer, GC gastric cancer, HCC hepatocellular carcinoma, HR hazard ratio, NOS Newcastle-Ottawa Scale, PC pancreatic cancer